Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Receives Notice of Allowance for US Patent Application on RNAi Agents

Premium

Alnylam Pharmaceuticals said this week that the US Patent and Trademark Office has issued a notice of allowance for a company patent application covering "certain chemically modified siRNAs of any length directed to any target, including siRNAs with sterol conjugates, for in vivo delivery."

The patent application, No. 20050107325, is entitled "Modified iRNA Agents," and specifically claims RNAi agents that "preferably include a monomer in which the ribose moiety has been replaced by a moiety other than ribose," its abstract states. "The inclusion of such a monomer can allow for modulation of a property of the … agent into which it is incorporated," for example by using the non-ribose moiety as a point to which a ligand or other entity, such as cholesterol, is directly or indirectly tethered.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.